Clinical trials: Plasma Cell Dyscrasias, active
Plasma Cell Disorder
Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing
The goal of this observational study is to study the genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand.
- Trial name
- genetics MM (NCT06330896)
- Volunteers
- 498 people
- Sponsor
- Siriraj Hospital
AL Amyloidosis
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down.
- Trial name
- NCT04504825
- Testing
- CAEL-101, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
- Where
- 90 sites in United States, Australia and 17 more
- Volunteers
- 125 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Plasma Cell Dyscrasias
The Indiana Myeloma Registry
This is a prospective, non-interventional, observational study. The purpose of this study is to collect data and bio-specimens that will support future research
- Trial name
- NCT03616483
- Testing
- This is a non-interventional trial
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Indiana University
Multiple Myeloma and Other Plasma Cell Neoplasms
Longitudinal Data Registry of Plasma Cell Dyscrasia
The goal of this multicenter observational study is to better understand the clinical and molecular characteristics, disease progression, treatment response, and clinical outcomes of patients with plasma cell dyscrasias…
- Trial name
- NCT06760052
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Shanghai Zhongshan Hospital
Plasma Cell Disorder
Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
The purpose of this study is to look at the safety, tolerability, and serum concentration of daratumumab administered subcutaneously in the thigh versus the abdomen in patients with plasma cell disorders.
- Trial name
- NCT07075510
- Testing
- Daratumumab Injection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Maryland, Baltimore
Plasma Cell Dyscrasias, Monoclonal Gammopathy of Undetermined Significance
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life.
- Conditions
- Plasma Cell Dyscrasias, Monoclonal Gammopathy of Undetermined Significance, AL Amyloidosis, Multiple Myeloma
- Trial name
- B-SCR-MM (NCT01408225)
- Testing
- tissue banking
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Plasma Cell Disorders
Registry of Patients With Plasma Cell Disorders
The goal of this observational study is to register patients with plasma cell disorders. The main questions it aims to answer are: The incidence of plasma cell disorders both before and after malignancy Time to progression of…
- Trial name
- Registry PCD (NCT06286215)
- Volunteers
- 750 people
- Sponsor
- Siriraj Hospital
AL Amyloidosis
BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)
Systemic light-chain (AL) amyloidosis is a plasma cell disorder characterized by the production of misfolded immunoglobulin light chains that deposit in organs and lead to progressive organ dysfunction.
- Trial name
- AL-004 (NCT07751471)
- Testing
- QLS4131
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Plasma Cell Dyscrasias
Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell Disorders
This study is an open-label, single-arm, dose-escalation and expansion, prospective clinical trial. It enrolls patients with relapsed/refractory plasma cell disorders, administers GPRC5D CAR-T cell therapy, follows up to observe…
- Trial name
- NCT07365059
- Testing
- GPRC5D CAR-T cell intravenous infusion
- Volunteers
- 18 people
- Sponsor
- Qi deng
Clonal Hematopoiesis of Indeterminate Potential, Monoclonal Gammopathy
Pre-malignant States to Hematologic Malignancies in Firefighters
The purpose of the study is to evaluate if firefighter exposure to hazardous compounds will increase the incidence of premalignant hematological states which subsequently increases the risk of the development of hematologic…
- Conditions
- Clonal Hematopoiesis of Indeterminate Potential, Monoclonal Gammopathy, Non Hodgkin Lymphoma, Leukemia
- Trial name
- NCT06870760
- Testing
- Monoclonal Gammopathy, Complete Blood Count with differential (CBC w/ diff), Clonal hematopoiesis (CHIP)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
AL Amyloidosis
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down.
- Trial name
- NCT04512235
- Testing
- CAEL-101, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
- Where
- 110 sites in United States, Australia and 17 more
- Volunteers
- 281 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Plasma Cell Disorder
High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
The purpose of this research is to evaluate whether HDAA in combination with a single dose of 100 mg/m2 IV melphalan followed by autologous stem cell transplantation (ASCT) is safe and effective for subjects with relapsed…
- Trial name
- NCT06313502
- Testing
- 75gm HDAA, 100gm HDAA, 125gm HDAA
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Arkansas
Multiple Myeloma, Plasma Cell Disorder
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
- Trial name
- NCT04879043
- Testing
- HDP-101
- Where
- 24 sites in United States, Germany and 3 more
- Volunteers
- 78 people
- Sponsor
- Heidelberg Pharma AG
Hematologic Malignancies, Inherited Disorders of Metabolism
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
- Conditions
- Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders
- Trial name
- NCT01351545
- Testing
- A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
- Where
- 142 sites in United States
- Volunteers
- 99,999 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
AL Amyloidosis, Plasma Cell Dyscrasia
Autologous Stem Cell Transplantation for Patients With AL Amyloidosis
This study mainly evaluated the efficacy and safety of autologous stem cell transplantation for the treatment of AL amyloidosis, the role of induction and maintenance therapy in autologous stem cell transplantation, and the…
- Trial name
- NCT04210791
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Nanjing University School of Medicine
Plasma Cell Dyscrasia
Pilot Trial of Homebound Stem Cell Transplantation
In this study, the investigators plan to see what happens when a person receives care in the home setting. They want to find out if caring for a patient who has been treated with an ASCT in the home setting is feasible.
- Trial name
- NCT02671448
- Testing
- Home monitoring teleconsult visits, Patient Reported Outcomes (PRO), Caregiver Reported Outcomes instruments
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center